Evidence map›Paper›PMID 40136342›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Downregulation of the Unfolded Protein Response Links Metformin Treatment to Good Clinical Outcomes in Colorectal Cancer Patients.

Mary L Fay, Chris Nicol, Christine Orr, Brooke Wilson, David Hurlbut, Harriet Feilotter, Scott Davey

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mary L FayDivision of Cancer Biology and Genetics, Sinclair Cancer Research Institute at Queen's University, Kingston, ON K7L 3N6, Canada.
Chris NicolDivision of Cancer Biology and Genetics, Sinclair Cancer Research Institute at Queen's University, Kingston, ON K7L 3N6, Canada.
Christine OrrDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0000-0001-7742-0810
Brooke WilsonDepartment of Oncology, Queen's University, Kingston, ON K7L 3N6, Canada.
David HurlbutDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0000-0002-8751-9539
Harriet FeilotterDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Scott DaveyDivision of Cancer Biology and Genetics, Sinclair Cancer Research Institute at Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0000-0001-8909-8064

Funding

Kingston Health Sciences Centre N/A
6 · The paper itself

Abstract

Type 2 diabetes is a risk factor for colorectal cancer (CRC) development and progression. However, metformin-treated diabetic CRC patients tend to have better clinical outcomes than those managed by other means. To better characterize the molecular underpinnings of metformin's protective effects, we performed a targeted transcriptomic analysis of primary CRC tissue samples (

Indexed as

Colorectal NeoplasmsDiabetes Mellitus, Type 2Hypoglycemic AgentsMetforminUnfolded Protein ResponseAgedDown-RegulationFemaleHumansMaleMiddle AgedTreatment OutcomeHypoglycemic AgentsMetformincolorectal cancermetformintype 2 diabetesunfolded protein response

Identifiers

PMID40136342
PMCPMC11941617

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.